Cystic fibrosis

Overview

Board takeaway: Schedule around airway clearance, position for comfortable breathing, and review respiratory reserve, bleeding risk, and drug interactions before surgery or sedation.

An autosomal recessive CFTR channel defect causing thick secretions in the lungs and pancreas. Chronic antibiotics and enzymes shape oral findings; lung function shapes sedation.

How does Cystic fibrosis affect dental management?

• Visit planning: Upright position, short visits; later-morning or afternoon appointments after airway clearance
• Sedation: Assess respiratory reserve, secretions, current infection, and prior anesthesia before sedation.
• Advanced lung disease: Respiratory depressants and positive-pressure rescue can pose particular risks in advanced lung disease; select drugs and setting with the CF/anesthesia team.
• Individual choice: CF alone is not an automatic ban on all sedation
• Bleeding assessment: liver disease or vitamin K malabsorption can prolong PT/INR; check before surgery.
• Antibiotics: Review current antibiotics, culture history, and drug interactions if systemic treatment of dental infection is indicated; ongoing pulmonary antibiotics do not replace definitive dental treatment
• Diabetes and saliva: Screen for CF-related diabetes; manage hyposalivation

Exam pearl

What is Cystic fibrosis?

An autosomal recessive disorder caused by CFTR dysfunction, which disrupts salt and water transport and produces thick secretions, especially affecting the lungs and pancreas.

What are the main systemic features of Cystic fibrosis?

• Genetics and diagnosis: CFTR variants (F508del is common); affects people of all ancestries. Diagnosis follows newborn screening or clinical suspicion with sweat chloride and/or genetic testing
• Lungs and pancreas: Chronic lung infection (Pseudomonas, Staphylococcus aureus), bronchiectasis; pancreatic insufficiency with malabsorption
• Other organs: Fat-soluble vitamin deficiency, CF-related diabetes, liver disease, male infertility
• Treatment: airway clearance, inhaled antibiotics, pancreatic enzymes, CFTR modulators (elexacaftor-tezacaftor-ivacaftor)

What oral findings occur in Cystic fibrosis?

• Caries balance: Lower caries in some patients (long-term antibiotics, salivary buffering), but sweet high-calorie diets and enzymes raise risk
• Enamel: Enamel hypoplasia and intrinsic staining (historic tetracycline use)
• Saliva and breathing: More calculus; enlarged submandibular glands; mouth breathing and open bite from sinus disease
• Individual risk: Assess each child individually: CF-related diabetes can also raise caries risk.

What can cause brown-gray banding on the teeth of a teenager with cystic fibrosis?

• Likely cause: Intrinsic tetracycline staining from earlier antibiotic courses; enamel hypoplasia from early illness can also occur.
• Current context: Newer CF patients rarely have this.

For Cystic fibrosis, which modern therapy should you know about?

• Therapy: CFTR modulators such as elexacaftor–tezacaftor–ivacaftor markedly improve lung function.
• Dental relevance: TRIKAFTA exposure increases with CYP3A inhibitors such as clarithromycin, erythromycin, and azole antifungals.
• Prescriber coordination: contact the CF prescriber before using interacting drugs; the label requires TRIKAFTA dose reduction with strong or moderate CYP3A inhibitors. TRIKAFTA prescribing information.
• Check the exact drug: Check the exact drug rather than assuming all macrolides or sedatives interact.
• Monitoring: The label also requires liver monitoring.

Sources

• Supplemental study guide: Pediatric Dental Study Guide: Cystic fibrosis
• Management of Dental Patients with Special Health Care Needs
• Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures*
• Supplemental genetics: MedlinePlus Genetics: cystic fibrosis
• Supplemental clinical source: Vertex: TRIKAFTA prescribing information (2026)